US Patent

US8252329 — Bioadhesive drug formulations for oral transmucosal delivery

Formulation · Assigned to AcelRx Pharmaceuticals Inc · Expires 2027-01-05 · 1y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects bioadhesive drug formulations for oral transmucosal delivery, including single dose applicators and devices for delivering the formulations to the oral mucosa.

USPTO Abstract

Bioadhesive drug formulations that adhere to an oral mucosal membrane of a subject are provided together with single dose applicators and devices for delivering the drug formulations to the oral mucosa, and methods for using the same.

Drugs covered by this patent

sufentanil-citrate (SUFENTANIL CITRATE)

Patent Metadata

Patent number: US8252329
Jurisdiction: US
Classification: Formulation
Expires: 2027-01-05
Drug substance claim: No
Drug product claim: Yes
Assignee: AcelRx Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.